| Ytd | -2.53% | |
| 1y | 69.29% |
| Open | 14.92 | Prev Close | 14.88 | Low | 14.55 | High | 15.38 | Mkt Cap | 513.11M |
| Vol | 251.57K | Avg Vol | 194.83K | EPS | -0.65 | P/E | -23.15 | Forward P/E | -10.90 |
| Beta | 1.80 | Short Ratio | 2.85 | Inst. Own | 82.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 15.61 | 200-d Avg | 15.20 | 1yr Est | 16.17 |
NPCE News
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus
Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday'
US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earning
HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintai
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopa
NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket appr
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform ra
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and inves
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. Whil
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offerin
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven b
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that ma
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
NeuroPace (NPCE) was a big mover last session on higher-than-average trading volume. The latest tren
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings a